Latest Intelligence on Pharmaceuticals and Healthcare in Switzerland

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Roche: poor results for NeoRecormon

Researchers have found that Roche's [ROCZ.S] anemia treatment NeoRecormon might worsen survival in head and neck cancer patients who undergo radiotherapy. Despite the poor findings, the study is unlikely to have any significant repercussions for NeoRecormon's rival erythropoietins, Amgen's [AMGN] Epogen and J&J's [JNJ] Procrit.

Published By Datamonitor
20 Oct 2003
CommentWire
CommentWire

Roche: Piramed acquisition strengthens its oncology and I&I portfolio

Roche has agreed to acquire Piramed for $160m plus a milestone payment of $15m, due upon the start of Phase II clinical trials for the company's oncology program. Piramed's oncology and immunology and inflammation programs will add to Roche's already strong portfolio in these therapy areas and the move is in line with Roche's strategy of pursuing these two fastest growing therapeutic segments.

Published By Datamonitor
15 Apr 2008
CommentWire
CommentWire

Roche: Pegasys effective 4 years post-treatment

Recently presented efficacy data for Roche's [ROCZ.S] Hepatitis C drug Pegasys will increase physician confidence in the drug. This will provide the company with an additional and powerful marketing tool in the competition with Schering-Plough's [SGP] PEG-Intron, which has little in the way of similar data currently available.

Published By Datamonitor
09 Jul 2003
CommentWire
CommentWire

Roche: negligible increase in pharmaceuticals

Published By Datamonitor
02 Mar 2001
CommentWire
CommentWire

Roche: making Pegasys fly in Europe

Roche can now market Pegaysys to EU hepatitis C sufferers. It should win market share from Schering-Plough's Peg Intron, which hit EU markets last year. But hepatitis C is increasingly being treated with combined pegylated interferon and ribavirin - so until Roche gains approval for its ribavirin variant, Copegus, Roche will not be able to fully displace Schering's patient capture.

Published By Datamonitor
25 Jun 2002
CommentWire
CommentWire

Roche: improved potential for MabThera

A phase III clinical trial of Roche's [ROCZg.VX] MabThera (rituximab) in patients below 60 years of age with aggressive non-Hodgkin's lymphoma was halted early because its primary efficacy endpoint was met two years earlier than expected. These trial results are likely to consolidate MabThera's position as the best-selling innovative agent for cancer.

Published By Datamonitor
08 Dec 2003
CommentWire
CommentWire

Roche: hoping for a better 2002

Much of the fall was due to the troubled vitamin and fine chemicals division, which Roche may well sell this year. However, the pharmaceutical division also had problems. Things may be better 2002, within the cardiovascular sphere at least. If weight loss drug Xenical is approved in type 2 diabetics, the market potential will be considerable.

Published By Datamonitor
01 Mar 2002
CommentWire
CommentWire

Roche: HIV announcement to dispel pipeline fears

Published By Datamonitor
21 Aug 2001
CommentWire
CommentWire

Roche: cautious start to metabolic syndrome development

JTT-705, which Roche is to license from Japan Tobacco, is a novel anti-dyslipidemic that will further enhance the company's cardiovascular risk factor offering. This latest move could ultimately place Roche in a potentially advantageous position in the growing metabolic syndrome market, though it marks only the start of a long process to increase its currently meager offering in this field.

Published By Datamonitor
21 Oct 2004
CommentWire
CommentWire

Roche: buying up for biotech boost

Roche has announced that it will acquire GlycArt for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen Roche's drug development capabilities and help maintain the large increases in sales drawn from its therapeutic anti-cancer antibodies.

Published By Datamonitor
20 Jul 2005

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.